Literature DB >> 19033592

Benefits and risks of drug treatments: how to combine the best evidence on benefits with the best data about adverse effects.

Jan P Vandenbroucke1, Bruce M Psaty.   

Abstract

Mesh：

Year:  2008        PMID： 19033592     DOI： 10.1001/jama.2008.723

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  34 in total

1.  Opioids in COPD: the 'whole picture' includes results from real-world, population-based observational studies.

Authors:  Nicholas T Vozoris; Sudeep S Gill; Denis E O'Donnell
Journal:  Br J Clin Pharmacol       Date:  2016-01-04       Impact factor: 4.335

Review 2.  Post-approval evaluation of effectiveness of risk minimisation: methods, challenges and interpretation.

Authors:  Anjan Kumar Banerjee; Inge M Zomerdijk; Stella Wooder; Simon Ingate; Stephen J Mayall
Journal:  Drug Saf       Date:  2014-01       Impact factor: 5.606

3.  Sources of information used by regulatory agencies on the generation of drug safety alerts.

Authors:  Carlos Alves; Ana Filipa Macedo; Francisco Batel Marques
Journal:  Eur J Clin Pharmacol       Date:  2013-07-27       Impact factor: 2.953

4.  Causal assessment of pharmaceutical treatments: why standards of evidence should not be the same for benefits and harms?

Authors:  Barbara Osimani; Fiorenzo Mignini
Journal:  Drug Saf       Date:  2015-01       Impact factor: 5.606

5.  An introduction to the fundamentals of cohort and case-control studies.

Authors:  John-Michael Gamble
Journal:  Can J Hosp Pharm       Date:  2014-09

6.  Safety of psychotropic medicines: contribution from observational evidence.

Authors:  H Verdoux
Journal:  Epidemiol Psychiatr Sci       Date:  2018-05-30       Impact factor: 6.892

7.  Risk minimization activities of centrally authorized products in the EU: a descriptive study.

Authors:  Inge M Zomerdijk; Fakhredin A Sayed-Tabatabaei; Gianluca Trifirò; Stella C F Blackburn; Miriam C J M Sturkenboom; Sabine M J M Straus
Journal:  Drug Saf       Date:  2012-04-01       Impact factor: 5.606

8.  Dose-specific adverse drug reaction identification in electronic patient records: temporal data mining in an inpatient psychiatric population.

Authors:  Robert Eriksson; Thomas Werge; Lars Juhl Jensen; Søren Brunak
Journal:  Drug Saf       Date:  2014-04       Impact factor: 5.606

Review 9.  Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence.

Authors:  J A Johnson; B Carstensen; D Witte; S L Bowker; L Lipscombe; A G Renehan
Journal:  Diabetologia       Date:  2012-04-04       Impact factor: 10.122

10.  Adverse gastrointestinal events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study.

Authors:  Robert J Campbell; Chaim M Bell; Susan E Bronskill; J Michael Paterson; Marlo Whitehead; Erica de L Campbell; Sudeep S Gill
Journal:  Drug Saf       Date:  2014-09       Impact factor: 5.606
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.